Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • Publication number: 20240041774
    Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 8, 2024
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Shogo HIRAOKA
  • Patent number: 11890092
    Abstract: A system, a wearable device, and a method are provided which can increase the accuracy of physiological metrics while detecting if the patient ingested digital medicine and/or improve performance of the wearable device. The wearable device can comprise machine executable instructions that when executed by the processor, cause the processor to perform various algorithms, such as, for example, at least one of a step count algorithm, a body angle algorithm, a heart rate algorithm, a peak finder algorithm, an adaptive thresholding algorithm, a heart rate variability algorithm, a R-R cleaning Algorithm, a deltaR-R cleaning algorithm, a merge twin interval algorithm, a split tall intervals algorithm, an absorb short intervals algorithm, a bimodal detection algorithm, and a resting algorithm.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: February 6, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Robert Azevedo, Neraj P. Bobra, Aditya Dua, Ronny X. Li, William A. Weeks
  • Publication number: 20240009186
    Abstract: Provided is a solution suitable for oral administration of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one(compound (I)) or a salt thereof. A solution for oral administration containing compound (I) or a salt thereof and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid and having pH 2.5-4.5.
    Type: Application
    Filed: March 27, 2023
    Publication date: January 11, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Ayako OKAMOTO
  • Patent number: 11870508
    Abstract: A system for tracking a product from origin to destination is disclosed. The system includes a probe that comprises two plates, a power source and a processor. The power source is controlled by the processor to produce an oscillating output at the plates. Using the oscillating voltage, the probe interrogates a device through capacitive coupling. The device includes a control unit, a memory unit, and first and second materials physically associated with the device for communication using capacitive coupling. Information associated with the device is transferred from the device to the probe through capacitive coupling between the first and second materials and the first and second plates, respectively.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: January 9, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Mark J. Zdeblick
  • Patent number: 11840512
    Abstract: Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles 2?(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuK? characteristic X-rays.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: December 12, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Naohiko Kanai, Takayuki Yasutomi, Ryosuke Hirota
  • Publication number: 20230390399
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s?1, as measured.
    Type: Application
    Filed: December 30, 2022
    Publication date: December 7, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
  • Publication number: 20230381194
    Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
    Type: Application
    Filed: August 2, 2023
    Publication date: November 30, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Akitsuna AKAGI, Kai SUZUKI, Atsuya NAKAMURA, Toru NISHIBAYASHI
  • Patent number: 11830615
    Abstract: A risk management system (RMS) device includes a RMS database and a RMS processor. The RMS processor includes a prescriber module to receive a request to enroll a patient in a RMS program of a therapeutic agent associated with multiple indications. The request includes a specification of at least one indication, and a confirmation of a diagnostic test conducted on the patient. The RMS processor also includes a patient module configured to generate a patient profile. The RMS processor also includes a database module configured to store the patient profile in the RMS database. The RMS processor also includes an authorization module configured to generate an authorization code indicating whether the patient is authorized to receive the therapeutic agent. The RMS processor also includes a communication module configured to transmit the authorization code to a pharmacy or a prescriber.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 28, 2023
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Frank S. Czerwiec, Amy Freedman, Keith Friend, Elaine A. O'Hara, Craig Ostroff, Marcelo De Freitas Santoro, Charles Shiner, Takeshi Watanabe, Miho Yamamoto, Christopher A. Zimmer
  • Patent number: 11819337
    Abstract: A system to track consumer patient adherence to a drug and dose form includes a tracking device, a computer system and a database. The tracking device, to process a plurality of Ingestible Event Marker (IEM) devices, wherein each IEM device includes an IEM storing an IEM identifier code, may include a first capacitive plate, a second capacitive plate, and a structure to position each IEM device in proximity to the first and second capacitive plates. The tracking device may be configured to interrogate each IEM, via capacitive coupling, as each IEM device passes through the structure. The computer system communicatively coupled to the tracking device may be configured to receive each IEM identifier code read from each interrogated IEM and the database to track each IEM may be configured to link each received IEM identifier code to additional information including an identifier of an active drug/medication.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: November 21, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: George M. Savage
  • Publication number: 20230338337
    Abstract: The invention provides biomarkers to predict effective treatment of cancer using an MDM2 antagonist. Identifying one or more of these biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an MDM2 antagonist. Accordingly, the invention relates generally to a companion diagnostic for MDM2 antagonist therapy. The biomarkers are: (i) BAP1; and/or (ii) CDKN2A; and/or (iii) one, two, three, four, five, six, seven, eight, nine, ten or more of: CXCL10, CXCL11, RSAD2, MX1, BATF2, IF144L, IFITM1, ISG15, CMPK2, IF127, CD74, IFIH1, CCRL2, IF144, HERC6, ISG20, IFIT3, HLA-C, OAS1, IF135, IRF9, EPSTI1, USP18, BST2, CSF1, C1S, DHX58, TRIM14, OASL, IRF7, LGALS3BP, DDX60, LAP3, LAMP3, PARP12, PARP9, SP110, PLSCR1, WARS, STAT1, IRF3, IRF5, MSC, JUN, SPI1, IRF1, COMMD3-BMI1, STAT2, RUNX3, SREBF1, FLI1 and BRCA1.
    Type: Application
    Filed: December 23, 2020
    Publication date: October 26, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Nicola FERRARI, Harpreet Kaur SAINI, Jong Sook AHN
  • Patent number: 11793419
    Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: October 24, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Jeremy Frank, Nikhil Pargaonkar, Raymond Schmidt, Robert Azevedo, Kurt Scheinpflug, Nikolaus Leist, Chris Dong, Hiren Patel, Peter Bjeletich, Robert Duck
  • Patent number: 11786600
    Abstract: The invention provides a CLIPTAC comprising: (a) a first portion comprising a ligand for an intracellular target protein; (b) a second portion comprising a ligand for an E3 ubiquitin ligase; and (c) a linker portion covalently coupling the first and second portions; wherein the linker comprises a covalent bond produced by a bioorthogonal click reaction between a compatible pair of reactive moieties. CLIPTAC precursor compositions and CLIPTAC precursors are also provided, together with pharmaceutical compositions comprising the CLIPTAC, CLIPTAC precursor compositions and CLIPTAC precursors, and methods of treatment using the same.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: October 17, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Thomas Daniel Heightman, Honorine Lebraud
  • Publication number: 20230322812
    Abstract: An object of the present invention is to provide a crystal of compound 1, which is useful as an antitumor agent, the crystal being stable, excellent in oral absorbability, highly chemically pure, and suitable for mass production. The present invention provides a crystal of compound 1 that exhibits an X-ray powder diffraction spectrum containing, at diffraction angles 2?±0.2°, characteristic peaks of at least 3 characteristic peaks selected from the group consisting of 5.8°, 9.8°, 12.2°, 14.0°, 15.3°, 21.1°, and 27.6°.
    Type: Application
    Filed: August 24, 2021
    Publication date: October 12, 2023
    Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takashi MITA, Daisuke TAKEDA
  • Publication number: 20230321030
    Abstract: Provided is a means useful for enjoying the physiological action of kaempferol. A plant extract contains 1 mg/g or more of a kaempferol aglycone on a dry-weight basis.
    Type: Application
    Filed: August 24, 2021
    Publication date: October 12, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yasutaka IKEDA, Tsubasa MIZOKAMI, Ryo SERIZAWA, Yasuhiro ABIRU, Naoto NORO
  • Publication number: 20230321113
    Abstract: The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 ?m, and a 90% cumulative particle diameter of 100 to 200 ?m.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 12, 2023
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shinsuke NAKAGAWA, Kai SUZUKI, Tadashi MUKAI
  • Publication number: 20230313313
    Abstract: The invention provides SKP2 as a biomarker to predict effective treatment of cancer using an MDM2 antagonist. Identifying this biomarker in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an MDM2 antagonist. Accordingly, the invention relates generally to a companion diagnostic for MDM2 antagonist therapy. The SKP2 biomarker may be measured directly, or indirectly by detection of a molecule that is functionally upstream or downstream of SKP2 and the level of which correlates with the level of the SKP2 biomarker, such as the detection of one or more SKP2 substrates.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 5, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Nicola FERRARI, Harpreet Kaur SAINI, Jong Sook AHN
  • Publication number: 20230303981
    Abstract: An object of the present invention is to provide a ventral hindgut organoid for producing a bladder organoid that comprises a layer structure of bladder epithelial cell types like the urinary bladder. An aspect of the present invention is to provide a method for producing a ventral hindgut organoid, comprising culturing a pluripotent stem cell with an inducer medium A containing activin A and GSK3? inhibitor to induce differentiation into definitive endoderm cells and culturing the definitive endoderm cells with an inducer medium B containing fibroblast growth factor, GSK3? inhibitor, and optionally further containing bone morphogenetic protein, and then culturing them in the presence of extracellular matrix with an inducer medium B containing fibroblast growth factor, GSK3? inhibitor, and optionally further containing bone morphogenetic protein to form a ventral hindgut organoid.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 28, 2023
    Applicants: RIKEN, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Minoru TAKASATO, Kazuhiro OFUJI, Filip Jos WYMEERSCH
  • Patent number: 11759470
    Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: September 19, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Akitsuna Akagi, Kai Suzuki, Atsuya Nakamura, Toru Nishibayashi
  • Patent number: 11759426
    Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: September 19, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Syed Asfar Mateen, Praveen Kumar Mididoddi, Shailly Mehrotra, Susan Elizabeth Shoaf, Salin Gupta, Kai Suzuki, Masahiro Hasegawa
  • Patent number: 11744481
    Abstract: A computer-implemented method is disclosed. The computer-implemented method comprises receiving, by a computer system, ingestible event marker (IEM) system information from a receiver worn by a subject, the IEM system information comprising information associated with ingestion of medication by the subject, wherein the receiver is configured to communicate with the computer system; receiving, by the computer system, contextual information associated with the subject; and calculating, by the computer system, a composite risk score based on the IEM system information and the contextual information associated with the subject.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: September 5, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yashar Behzadi, Alireza Akhbardeh, Clifford Lewis